Different concentrations of sunitinib were used to treat ccRCC cell lines with NUDT1 stably knocked down and NUDT1 stably overexpressed, and construct a drug sensitivity curve based on the experimental results. Here, NUDT1 is linked to nonpapillary renal cell carcinoma.